13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
26 檔
3.4%
At the close of Q1 2026, Alphabet Inc. disclosed equity holdings valued at approximately $99.1B, spread across 26 reported holdings.
In Q1 2026, Alphabet Inc. adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 6 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including CME, PL, ASTS) accounted for 3.4% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CME | Cme Group Inc | Stock-Financials | 25.63% | -24.85% | — | |
| 2 | PL | Planet Labs Pbc | Stock-Industrials | 24.53% | -23.35% | +10.35% | |
| 3 | ASTS | Ast Spacemobile Inc | Stock-Tech | 18.46% | -17.66% | — | |
| 4 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.97% | -7.41% | -1.57% | |
| 5 | ARM | Arm Holdings Plc-adr | Stock-Tech | 7.39% | -6.69% | — | |
| 6 | FRSH | Freshworks Inc-cl A | Stock-Other | 3.24% | -3.07% | — | |
| 7 | PATH | Uipath Inc - Class A | Stock-Tech | 1.94% | -1.86% | — | |
| 8 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 1.75% | -1.66% | — | |
| 9 | PAYP | Paypay CORP | Stock-Other | 1.66% | -1.61% | — | |
| 10 | GTLB | Gitlab Inc-cl A | Stock-Tech | 1.47% | -1.39% | — | |
| 11 | PRME | Prime Medicine Inc | Stock-Other | 1.44% | -1.38% | — | |
| 12 | LIFE | Ethos Technologies Inc Cl-a | Stock-Other | 1.05% | -0.98% | — | |
| 13 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.03% | -0.99% | — | |
| 14 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.63% | -0.61% | — | |
| 15 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.39% | -0.36% | -0.29% | |
| 16 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.28% | -0.27% | -8.14% | |
| 17 | VERA | Vera Therapeutics Inc | Stock-Other | 0.24% | -0.23% | — | |
| 18 | SANA | Sana Biotechnology Inc | Stock-Other | 0.20% | -0.19% | — | |
| 19 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.19% | -0.18% | — | |
| 20 | LYEL | Lyell Immunopharma Inc | Stock-Other | 0.15% | -0.15% | — | |
| 21 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.14% | -0.13% | — | |
| 22 | FIG | Figma Inc-cl A | Stock-Other | 0.11% | -0.11% | — | |
| 23 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.05% | -0.05% | — | |
| 24 | HYPR | Hyperfine Inc | Stock-Other | 0.02% | -0.02% | — | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.02% | -0.02% | — | |
| 26 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.02% | -0.02% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PL | Planet Labs Pbc | +0.1% | +10.35% | Add |
| 2 | HYPR | Hyperfine Inc | 0% | — | Unchanged |
| 3 | TNYA | Tenaya Therapeutics Inc | 0% | — | Unchanged |
| 4 | AUTL | Autolus Therapeutics PLC | 0% | — | Unchanged |
| 5 | SPRO | Spero Therapeutics Inc | 0% | — | Unchanged |
| 6 | RLAY | Relay Therapeutics Inc | -0.1% | -0.29% | Trim |
| 7 | OSCR | Oscar Health Inc - Class A | -0.1% | — | Unchanged |
| 8 | BEAM | Beam Therapeutics Inc | -0.2% | — | Unchanged |
| 9 | GLUE | Monte Rosa Therapeutics Inc | -0.2% | -8.14% | Trim |
| 10 | FIG | Figma Inc-cl A | -0.2% | — | Unchanged |
| 11 | LYEL | Lyell Immunopharma Inc | -0.2% | — | Unchanged |
| 12 | VERA | Vera Therapeutics Inc | -0.2% | — | Unchanged |
| 13 | SANA | Sana Biotechnology Inc | -0.2% | — | Unchanged |
| 14 | BBOT | Bridgebio Oncology Therapeut | -0.7% | — | Unchanged |
| 15 | PRME | Prime Medicine Inc | -0.8% | — | Unchanged |
| 16 | ARM | Arm Holdings Plc-adr | -0.9% | — | Unchanged |
| 17 | MAZE | Maze Therapeutics Inc | -1.2% | — | Unchanged |
| 18 | TEM | Tempus Ai Inc-cl A | -1.8% | — | Unchanged |
| 19 | RVMD | Revolution Medicines Inc | -2.4% | -1.57% | Trim |
| 20 | GTLB | Gitlab Inc-cl A | -2.5% | — | Unchanged |
| 21 | PATH | Uipath Inc - Class A | -2.5% | — | Unchanged |
| 22 | FRSH | Freshworks Inc-cl A | -4.5% | — | Unchanged |
| 23 | ASTS | Ast Spacemobile Inc | -6.7% | — | Unchanged |
| 24 | CME | Cme Group Inc | — | NEW | New buy |
| 25 | DXCM | Dexcom Inc | — | EXIT | Sold out |
| 26 | PAYP | Paypay CORP | — | NEW | New buy |
| 27 | LIFE | Ethos Technologies Inc Cl-a | — | NEW | New buy |
| 28 | WGS | Genedx Holdings CORP | — | EXIT | Sold out |
| 29 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 30 | QNCX | Quince Therapeutics, Inc. | — | EXIT | Sold out |
| 31 | FULC | Fulcrum Therapeutics Inc | — | EXIT | Sold out |
| 32 | RGEN | Repligen CORP | — | EXIT | Sold out |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 26 disclosed positions in Q1 2026.
During Q1 2026, Alphabet Inc.'s top holdings by market value included CME (25.6%)、PL (24.5%)、ASTS (18.5%). The largest single position, CME, represented 25.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CME
市值: $1.0B
Top Position Liquidated / Trimmed
DXCM
前期市值: $68.8M
In Q1 2026, Alphabet Inc. made 13 total portfolio adjustments, initiating 3 new buys, adding to 1 positions, trimming 3 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.